{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T19:28:57Z","timestamp":1777404537065,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T00:00:00Z","timestamp":1629244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.ygyno.2021.08.001","type":"journal-article","created":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T02:28:38Z","timestamp":1629772118000},"page":"162-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Platinum resistance in gynecologic malignancies: Response, disease free and overall survival are predicted by biochemical signature: A metabolomic analysis"],"prefix":"10.1016","volume":"163","author":[{"given":"Paulo","family":"D'Amora","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismael Dale C.G.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishnansu S.","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert E.","family":"Bristow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Cappuccini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven S.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcia B.","family":"Salzgeber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula J.","family":"Addis-Bernard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton M.","family":"Palma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirce M.L.","family":"Marchioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio A.F.","family":"Carioca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristine R.","family":"Penner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Alldredge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Longoria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Nagourney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.ygyno.2021.08.001_bb0005","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.7150\/jca.40590","article-title":"The prevalence and associated factors for liver metastases, development and prognosis in newly diagnosed epithelial ovarian cancer: a large population-based study from the SEER database","volume":"11","author":"Hussain","year":"2020","journal-title":"J. Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2021.08.001_bb0010","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2021.08.001_bb0015","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1136\/ijgc-00009577-200209000-00008","article-title":"FIGO stage III and IV uterine papillary serous carcinoma: impact of residual disease on survival","volume":"12","author":"Memarzadeh","year":"2002","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2021.08.001_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2021.08.001_bb0025","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1525-1438.2006.00746.x","article-title":"Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study","volume":"17","author":"Sovak","year":"2007","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2021.08.001_bb0030","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","article-title":"Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin","volume":"9","author":"Markman","year":"1991","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2021.08.001_bb0035","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ygyno.2013.09.021","article-title":"Applicability of the concept of \u201cplatinum sensitivity\u201d to recurrent endometrial cancer: the SGSG-012\/GOTIC-004\/Intergroup study","volume":"131","author":"Nagao","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.08.001_bb0040","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ygyno.2008.09.034","article-title":"Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer","volume":"112","author":"Muggia","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2021.08.001_bb0045","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.canlet.2014.01.005","article-title":"Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy?","volume":"346","author":"Bowden","year":"2014","journal-title":"Cancer Lett."},{"issue":"20","key":"10.1016\/j.ygyno.2021.08.001_bb0050","doi-asserted-by":"crossref","first-page":"8073","DOI":"10.1093\/nar\/17.20.8073","article-title":"Repair synthesis by human cell extracts in DNA damaged by cis- and trans-diamminedichloroplatinum (II)","volume":"17","author":"Hansson","year":"1989","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.ygyno.2021.08.001_bb0055","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/nar\/18.1.35","article-title":"Complementation of the xeroderma pigmentosum DNA repair synthesis defect with Escherichia coli UvrABC proteins in a cell-free system","volume":"18","author":"Hansson","year":"1990","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"10.1016\/j.ygyno.2021.08.001_bb0060","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert","year":"1989","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2021.08.001_bb0065","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"9","key":"10.1016\/j.ygyno.2021.08.001_bb0070","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1038\/sj.bjc.6601336","article-title":"Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics","volume":"89","author":"Nagourney","year":"2003","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2021.08.001_bb0075","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1006\/gyno.2002.6855","article-title":"Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients","volume":"88","author":"Nagourney","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.001_bb0080","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/nprot.2011.319","article-title":"Web-based inference of biological patterns, functions, and pathways from metabolomic data using MetaboAnalyst","volume":"6","author":"Xia","year":"2011","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ygyno.2021.08.001_bb0085","doi-asserted-by":"crossref","first-page":"W71","DOI":"10.1093\/nar\/gkq329","article-title":"MSEA: a web-based tool to identify biologically meaningful patterns in quantitative metabolomic data","volume":"38","author":"Xia","year":"2010","journal-title":"Nucleic Acids Res."},{"issue":"9","key":"10.1016\/j.ygyno.2021.08.001_bb0090","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.2337\/db15-1720","article-title":"A predictive metabolic signature for the transition from gestational diabetes mellitus to type 2 diabetes","volume":"65","author":"Allalou","year":"2016","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.ygyno.2021.08.001_bb0095","first-page":"77","article-title":"The effect of normalization of plasma amino acids on hepatic encephalopathy in man","volume":"80","author":"Fischer","year":"1976","journal-title":"Surgery"},{"issue":"60","key":"10.1016\/j.ygyno.2021.08.001_bb0100","doi-asserted-by":"crossref","first-page":"31664","DOI":"10.18632\/oncotarget.25839","article-title":"Inborn-like errors of metabolism are determinants of breast cancer risk, clinical response and survival: a study of human biochemical individuality","volume":"9","author":"da Silva","year":"2018","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.ygyno.2021.08.001_bb0105","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","article-title":"Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin","volume":"9","author":"Markman","year":"1991","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2021.08.001_bb0110","first-page":"1147","article-title":"Further observations on the effects of cancer chemotherapeutic agents on the in vitro dehydrogenase activity of cancer tissue","volume":"14","author":"Black","year":"1954","journal-title":"J. Natl. Cancer Inst."},{"issue":"24","key":"10.1016\/j.ygyno.2021.08.001_bb0115","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJM197806152982401","article-title":"Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs","volume":"298","author":"Salmon","year":"1978","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ygyno.2021.08.001_bb0120","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/bjc.1972.33","article-title":"Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics","volume":"26","author":"Kerr","year":"1972","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2021.08.001_bb0125","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11864-006-0045-2","article-title":"Ex vivo programmed cell death and the prediction of response to chemotherapy","volume":"7","author":"Nagourney","year":"2006","journal-title":"Curr. Treat. Options in Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2021.08.001_bb0130","first-page":"4453","article-title":"Functional profiling to select chemotherapy in untreated, advanced, or metastatic non-small cell lung cancer","volume":"32","author":"Nagourney","year":"2012","journal-title":"Anticancer Res."},{"issue":"5","key":"10.1016\/j.ygyno.2021.08.001_bb0135","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell."},{"issue":"9140","key":"10.1016\/j.ygyno.2021.08.001_bb0140","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(98)04119-1","article-title":"ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"9332","key":"10.1016\/j.ygyno.2021.08.001_bb0145","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(02)09738-6","volume":"360","year":"2002","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ygyno.2021.08.001_bb0150","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2000.18.1.106","article-title":"Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study","volume":"18","author":"Muggia","year":"2000","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.08.001_bb0155","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1006\/gyno.2002.6850","article-title":"Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma","volume":"88","author":"Rose","year":"2003","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2021.08.001_bb0160","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/CAD.0000000000000042","article-title":"The combination of gemcitabine and carboplatin shows similar efficacy in the treatment of platinum-resistant and platinum-sensitive recurrent epithelial ovarian cancer patients","volume":"25","author":"Safra","year":"2014","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.ygyno.2021.08.001_bb0165","unstructured":"Lichter-Konecki U, Caldovic L, Morizono H, Simpson K. Ornithine Transcarbamylase Deficiency. 2013 Aug 29 [updated 2016 Apr 14]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, Amemiya A. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993\u20132021. (PMID: 24006547)."},{"issue":"6","key":"10.1016\/j.ygyno.2021.08.001_bb0170","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.cell.2018.07.019","article-title":"Urea cycle dysregulation generates clinically relevant genomic and biochemical signatures","volume":"174","author":"Lee","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ygyno.2021.08.001_bb0175","first-page":"1","article-title":"Tryptophan catabolism in epithelial ovarian carcinoma","volume":"14","author":"Smith","year":"2019","journal-title":"Trends Cancer Res."},{"key":"10.1016\/j.ygyno.2021.08.001_bb0180","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.lfs.2019.03.004","article-title":"Wide spectrum targeted metabolomics identifies potential ovarian cancer biomarkers","volume":"222","author":"Plewa","year":"2019","journal-title":"Life Sci."},{"issue":"5","key":"10.1016\/j.ygyno.2021.08.001_bb0185","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11306-018-1354-8","article-title":"Predicting ovarian cancer recurrence by plasma metabolic profiles before and after surgery","volume":"14","author":"Zhang","year":"2018","journal-title":"Metabolomics"},{"issue":"8","key":"10.1016\/j.ygyno.2021.08.001_bb0190","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1158\/1078-0432.CCR-16-1647","article-title":"Integrative systemic and local metabolomics with impact on survival in high-grade serous ovarian cancer","volume":"23","author":"Bachmayr-Heyda","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ygyno.2021.08.001_bb0195","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cmet.2018.09.002","article-title":"PML-regulated mitochondrial metabolism enhances chemosensitivity in human ovarian cancers","volume":"29","author":"Gentric","year":"2019","journal-title":"Cell Metab."},{"key":"10.1016\/j.ygyno.2021.08.001_bb0200","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s42003-019-0508-1","article-title":"Targeting of lipid metabolism with a metabolic inhibitor cocktail eradicates peritoneal metastases in ovarian cancer cells","volume":"2","author":"Chen","year":"2019","journal-title":"Commun Biol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821006466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821006466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:58:56Z","timestamp":1758772736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825821006466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0090825821006466"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.08.001","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Platinum resistance in gynecologic malignancies: Response, disease free and overall survival are predicted by biochemical signature: A metabolomic analysis","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}